Info
Advanced drug delivery strategies for targeting chronic inflammatory lung diseases / / Dinesh Kumar Chellappan, Kavita Pabreja and Md. Faiyazuddin, editors
| Advanced drug delivery strategies for targeting chronic inflammatory lung diseases / / Dinesh Kumar Chellappan, Kavita Pabreja and Md. Faiyazuddin, editors |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2022] |
| Descrizione fisica | 1 online resource (652 pages) |
| Disciplina | 615.6 |
| Soggetto topico |
Drug delivery systems
Lungs - Diseases - Treatment Nanoparticles Malalties del pulmó Dispositius d'administració de medicaments |
| Soggetto genere / forma | Llibres electrònics |
| ISBN |
981-16-4392-X
981-16-4391-1 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- About the Editors -- 1: An Introduction to Respiratory Diseases and an Emerging Need for Efficient Drug Delivery Systems -- 1.1 Current Treatments for Respiratory Diseases -- 1.1.1 Bronchodilators -- 1.1.2 Corticosteroids -- 1.1.3 Antibiotics -- 1.1.4 Bronchodilators -- 1.2 Challenges to the Current Treatment of Drugs -- 1.2.1 Asthma -- 1.2.2 Chronic Obstructive Pulmonary Disease (COPD) -- 1.2.3 Interstitial Lung Diseases (ILDs) -- 1.2.4 Cystic Fibrosis (CF) -- 1.2.5 Lung Cancer -- 1.2.6 Respiratory Infections -- 1.3 Pulmonary Drug Delivery Systems -- 1.4 Limitations of the Drug Delivery Systems -- 1.5 The Need of Novel Drug Delivery Systems -- 1.6 Conclusion -- References -- 2: Inflammatory Respiratory Diseases: Correlation Between Lung Cancer and COVID-19 -- 2.1 Epidemiology -- 2.1.1 Introduction -- 2.1.2 Incidence -- 2.1.3 Mortality -- 2.1.4 Survival -- 2.2 Lung Cancer Among Never Smokers -- 2.2.1 Risk Factors -- 2.2.1.1 Passive Smoking -- 2.2.2 Cooking Fumes -- 2.2.3 Inherited Genetic Susceptibility -- 2.2.4 Preexisting Lung-Related Disease -- 2.2.5 Clinical Profile of Lung Cancer Among Never Smokers -- 2.3 Lung Cancer Screening, Diagnosis, and Treatment -- 2.3.1 Screening -- 2.3.2 Diagnosis -- 2.3.2.1 PET with Computed Tomography (PET-CT) -- 2.3.2.2 Magnetic Resonance Imaging (MRI) -- 2.3.3 Bronchoscopy -- 2.3.3.1 Fiberoptic Bronchoscopy -- 2.3.4 Endobronchial Ultrasound (EBUS) and Endoscopic (Esophageal) Ultrasound (EUS) -- 2.3.5 Transthoracic Needle Biopsy -- 2.3.5.1 Treatment -- 2.3.5.2 Surgery -- 2.3.5.3 Chemotherapy -- 2.3.5.4 Targeted Therapy -- 2.3.5.5 Immunotherapy -- 2.3.5.6 Radiation -- 2.4 Lung Cancer and COVID-19 -- 2.4.1 Introduction -- 2.4.2 Lung Cancer to a COVID-19 Risk Factor -- 2.4.3 Why Are Lung Cancer Patients Prone to Getting Infected with COVID-19?.
2.4.4 Lung Cancer Management During Diagnosis and Staging -- 2.5 Conclusion -- References -- 3: Advancements in Translational Respiratory Research Using Nanotechnology -- 3.1 Introduction -- 3.2 Advancements in Translational Respiratory Research (TRR) -- 3.3 Overview of Nanomedicine and Nanotechnology -- 3.3.1 Types of Nanoparticles -- 3.3.1.1 Carbon-Based Nanoparticles -- 3.3.1.2 Metal Nanoparticles -- 3.3.1.3 Ceramic Nanoparticles -- 3.3.1.4 Semiconductor Nanoparticles -- 3.3.1.5 Polymeric Nanoparticles -- 3.3.1.6 Lipid-Based Nanoparticles -- 3.3.2 Synthesis of Nanoparticles -- 3.3.2.1 Bottom-Up Method -- 3.3.2.2 Top-Down Method -- 3.3.3 Characterization of Nanoparticles -- 3.4 Inhalation Drug Delivery -- 3.4.1 Barriers to the Inhalation Drug Delivery System -- 3.4.2 Nanoparticles in Inhalation Drug Delivery -- 3.4.3 Clinical Studies on Inhalation Drug Delivery -- 3.5 Oligonucleotide Therapy -- 3.5.1 Antisense Oligonucleotides (ASOs) -- 3.5.2 Short Interfering RNA (siRNA) -- 3.5.3 MicroRNA (miRNA) -- 3.5.4 Aptamers -- 3.5.5 Cytosine-Guanine Dinucleotide (CpG) Oligonucleotides -- 3.5.6 Delivery of Oligonucleotide Therapy -- 3.5.7 Clinical Studies on Oligonucleotide Therapy -- 3.6 Photodynamic Therapy (PDT) -- 3.6.1 Nanoparticles in PDT -- 3.6.2 Clinical Studies on Photodynamic Therapy -- 3.7 Future Prospects -- 3.8 Conclusion -- References -- 4: Chemical Moieties as Advanced Therapeutics for Targeting Respiratory Disorders -- 4.1 Introduction -- 4.2 Indole-Based Chemical Compounds for Managing Respiratory Disorders -- 4.3 Azole-Based Chemical Compounds for Managing Respiratory Disorders -- 4.4 Chromone-Based Conjugates for Capping Respiratory Disorders -- 4.5 Flavonoid-Based Conjugates for Capping Respiratory Disorders -- 4.6 Terpenoid-Based Conjugates for Capping Respiratory Disorders -- 4.7 Alkaloids for Capping Respiratory Disorders. 4.8 Essential Patented Molecules for Ameliorating Respiratory Disorders -- 4.9 Conclusion -- References -- 5: Phytochemicals and their Nanoformulations Targeted for Pulmonary Diseases -- 5.1 Introduction -- 5.2 Phytochemical Nanoformulations Targeted for Lung Diseases -- 5.2.1 Curcumin -- 5.2.2 Resveratrol -- 5.2.3 Naringenin -- 5.2.4 (-)-Epigallocatechin-3-O-Gallate (EGCG) -- 5.2.5 Berberine -- 5.2.6 Celastrol -- 5.3 Conclusion and Future Prospects -- References -- 6: Nanocarriers: An Advanced and Highly Effective Approach for Targeting Chronic Lung Diseases -- 6.1 Introduction -- 6.2 Advanced Drug Delivery and Its Implication in Chronic Inflammatory Lung Disease -- 6.3 Nanocarriers Investigated in Advanced Drug Delivery for Targeting Chronic Lung Disease -- 6.3.1 Liposomes -- 6.3.2 Dendrimers -- 6.3.3 Polymeric Nanoparticles -- 6.3.4 Micelles -- 6.3.5 Carbon Nanotubes -- 6.3.6 Quantum Dots -- 6.3.7 Exosomes -- 6.3.8 Solid Lipid Nanoparticles -- 6.4 Synthetic Approaches of Polymeric Nanoparticle Formulation -- 6.5 Drugs Delivered Through Advanced Drug Delivery Strategies: Nanocarriers -- 6.6 Conclusions and Future Prospects -- References -- 7: Vesicular Drug Delivery Systems in Respiratory Diseases -- 7.1 Introduction -- 7.2 Global Prevalence of Major Respiratory Diseases -- 7.3 Conventional Therapies Used for Respiratory Diseases -- 7.4 Antibiotics -- 7.5 Anti-Inflammatory Drugs -- 7.6 Bronchodilators -- 7.7 Gene Therapy -- 7.8 Vesicular Drug Delivery System (VDDS) for Respiratory Disease Treatment -- 7.8.1 Liposomes -- 7.8.2 Virosomes -- 7.8.3 Niosomes -- 7.8.4 Proniosomes -- 7.8.5 Archaesome -- 7.8.6 Ethosomes -- 7.8.7 Others -- 7.9 Conclusion and Future Perspective -- References -- 8: Nanoparticles in Chronic Respiratory Diseases -- 8.1 Introduction -- 8.1.1 Chronic Respiratory Disease -- 8.1.2 Nanoparticle Size for Alveoli Delivery. 8.2 Lipid-Based Nanoparticle -- 8.2.1 Liposomes -- 8.2.2 Lipid Polymer Hybrid -- 8.2.3 Solid Lipid Nanoparticle -- 8.2.4 Nanostructured Lipid Carrier -- 8.3 Polysaccharides-Based Nanoparticles -- 8.4 Polymer-Based Nanoparticles (PNS) -- 8.5 Dendrimers -- 8.6 Inorganic Nanoparticles -- 8.6.1 Development of Inorganic Nanoparticles -- 8.6.1.1 Precipitation of Salts in Aqueous Media -- 8.6.1.2 Hydrothermal Method -- 8.6.1.3 Microemulsion Method -- 8.6.1.4 Polyol Process -- 8.6.1.5 Thermal Decomposition -- 8.6.2 Inorganic-Based Nanomaterials -- 8.6.2.1 Carbon Nanotubes -- 8.6.2.2 Gold Nanoparticles -- 8.6.2.3 Silver Nanoparticles -- 8.6.2.4 Platinum Nanoparticles -- 8.6.2.5 Magnetic Nanoparticles (MNPs) -- 8.6.2.6 Iron-Oxide Nanoparticles -- 8.6.2.7 Zinc Oxide Nanoparticles -- 8.6.2.8 Copper Oxide Nanoparticle -- 8.6.3 Inorganic Nanoparticles in Chronic Respiratory Diseases -- 8.7 Advanced Nanomedicine for Chronic Respiratory Diseases -- 8.7.1 Clinical Studies for Targeted Drug Delivery -- 8.7.1.1 Cystic Fibrosis -- 8.7.1.2 Lung Cancer -- 8.7.1.3 Asthma -- 8.7.2 Theranostics (Diagnosis and Imaging Based on Nanotechnology) -- 8.8 Conclusion -- References -- 9: Applications of Nanotechnology in Pulmonary Disease Diagnosis -- 9.1 Introduction -- 9.2 Promising Nanotechnological Interventions for Pulmonary Disease Diagnosis -- 9.2.1 Nanoparticle-Based Nano-Platforms for Diagnostic Imaging in Pulmonary Diseases -- 9.2.1.1 Gold NPs -- 9.2.1.2 Iron Oxide NPs -- 9.2.1.3 Polymeric NPs -- 9.2.1.4 Silica-Based NPs -- 9.2.1.5 Manganese Oxide NPs -- 9.2.1.6 Gadolinium-Based NPs -- 9.2.1.7 Miscellaneous -- 9.3 Nano-Biosensors for Pulmonary Disease Diagnosis -- 9.3.1 Nano-Biosensors for the Diagnosis of Tuberculosis -- 9.3.2 Nano-Biosensors for the Diagnosis of Lung Cancer -- 9.3.3 Nano-Biosensors for Diagnosis of Pulmonary Arterial Hypertension. 9.4 Quantum Dots/Nanocrystal Fluorophores-Based Nano-Platforms for Pulmonary Disease Diagnosis -- 9.5 Conclusion and Future Perspectives -- References -- 10: Nanotechnology in Pulmonary Disease Diagnosis -- 10.1 Introduction -- 10.2 Nanotechnology as a Diagnosis Tool -- 10.2.1 Ex Vivo Diagnosis -- 10.2.2 In Vivo Diagnosis -- 10.3 Nanotechnology in the Diagnosis of Pulmonary Diseases -- 10.4 Summary and Conclusion -- References -- 11: Recent Trends in Nanomedicine for Diagnosis and Treatment of Pulmonary Diseases -- 11.1 Introduction -- 11.1.1 Classification of Respiratory Diseases -- 11.1.2 Nanomedicine -- 11.1.3 Application of Nanomedicine in Respiratory Diseases -- 11.1.4 Diagnosis and Treatment -- 11.1.5 Obstructive Pulmonary Diseases -- 11.1.6 Pulmonary Tuberculosis -- 11.1.7 Lung Cancer -- 11.2 Targeted Drug Delivery in Pulmonary Diseases -- 11.3 Types of Nanoparticle-Based Treatment for Pulmonary Diseases -- 11.3.1 Solid Lipid Nanoparticles (SLN) -- 11.3.2 Polymeric Nanoparticles -- 11.4 Conclusion and Future Perspectives -- References -- 12: Strategies for Enhanced Drug Targeting to Inflamed Lungs: Novel Perspectives -- 12.1 Introduction -- 12.2 Anatomy and Physiology of Human Lungs -- 12.2.1 Bronchial Tree -- 12.2.1.1 Tracheal Airways -- 12.2.1.2 Bronchi and Bronchioles -- 12.2.2 Alveoli -- 12.2.3 Pulmonary Blood Circulation -- 12.2.4 Physiology of Lungs -- 12.2.4.1 Pulmonary Mechanics -- 12.2.4.2 Inspiration -- 12.2.4.3 Expiration -- 12.2.4.4 Gas Exchange -- 12.3 Chronic Inflammatory Lung Diseases -- 12.3.1 Asthma -- 12.3.1.1 Pathogenesis of Asthma -- 12.3.2 Chronic Obstructive Pulmonary Disease (COPD) and Emphysema -- 12.3.2.1 Pathogenesis of COPD (Chronic Bronchitis and Emphysema) -- 12.3.3 Idiopathic Pulmonary Fibrosis (IPF) -- 12.3.3.1 Pathogenesis of IPF -- 12.4 Nanodiagnosis of CILD. 12.5 Strategies for Enhanced Drug Targeting to Inflamed Lungs. |
| Record Nr. | UNINA-9910743341503321 |
| Singapore : , : Springer, , [2022] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
BMC pulmonary medicine
| BMC pulmonary medicine |
| Pubbl/distr/stampa | London, : BioMed Central, [2001]- |
| Soggetto topico |
Lungs - Diseases
Lung Diseases Malalties del pulmó |
| Soggetto genere / forma |
Periodical
Fulltext Internet Resources. Periodicals. Revistes electròniques. |
| ISSN | 1471-2466 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
BioMed Central pulmonary medicine
Pulmonary medicine |
| Record Nr. | UNINA-9910146812903321 |
| London, : BioMed Central, [2001]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiac considerations in chronic lung disease / / edited by Surya P. Bhatt
| Cardiac considerations in chronic lung disease / / edited by Surya P. Bhatt |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Humana, , 2020 |
| Descrizione fisica | 1 online resource (xi, 272 pages) : illustrations |
| Disciplina | 616.12 |
| Collana | Respiratory Medicine |
| Soggetto topico |
Cardiopulmonary system - Diseases
Lungs - Diseases - Complications Chronic diseases Cardiovascular Physiological Phenomena Lung Chronic Disease Cardiovascular System Cardiology Sistema cardiovascular Malalties del pulmó Malalties cròniques Cardiologia Medicina intensiva |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-43435-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Epidemiology of CLD and CVD -- Origins of Cardiopulmonay Disease in Early Life -- Gender Differences -- Genetics -- Physiology: Heart-Lung Interactions -- Pathophysiology of Coronary Artery Disease in CLD -- Pathophysiology of Heart Failure in CLD -- Pathophysiology of Right Heart Disease in CLD -- Extracardiac Cardiovascular Disease: Cerebrovascular Disease, Peripheral Arterial Disease -- Clinical Manifestations and Diagnosis -- Imaging -- Functional Evaluation: Cardiopulmonary Exercise Testing -- Prognosis: Impact of CVD on CLD and CLD on CVD -- Therapy and Medication Interactions -- Acute Exacerbations -- Lung Transplantation -- Future Perspectives. |
| Record Nr. | UNINA-9910407729403321 |
| Cham : , : Springer International Publishing : , : Imprint : Humana, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Cardiopulmonary monitoring : basic physiology, tools, and bedside management for the critically ill / / Sheldon Magder [and three others] editors
| Cardiopulmonary monitoring : basic physiology, tools, and bedside management for the critically ill / / Sheldon Magder [and three others] editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (952 pages) |
| Disciplina | 612.1 |
| Soggetto topico |
Cardiopulmonary system - Physiology
Cardiopulmonary system - Diseases Patient monitoring Malalties del pulmó Malalties del cor Monitoratge de pacients |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-73387-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910495193803321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Chronic Lung Diseases : Pathophysiology and Therapeutics / / edited by Sheikh Rayees, Inshah Din, Gurdarshan Singh, Fayaz A Malik
| Chronic Lung Diseases : Pathophysiology and Therapeutics / / edited by Sheikh Rayees, Inshah Din, Gurdarshan Singh, Fayaz A Malik |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (VIII, 180 p. 6 illus., 4 illus. in color.) |
| Disciplina | 780 |
| Soggetto topico |
Medicine
Biomedicine, general Malalties del pulmó Malalties cròniques |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-3734-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1 -- Therapeutic Advances in the Management of Pulmonary Arterial Hypertension -- Chapter 2 -- Asthma: Pathophysiology, Current Status and Therapeutics -- Chapter 3 -- Cystic Fibrosis: Biology and Therapeutics -- Chapter 4 -- Chronic Pneumonia -- Chapter 5 -- Tuberculosis -- Chapter 6 -- Lung cancer – Pathophysiology and Current Advancements in Therapeutics -- Chapter 7 -- Acute Respiratory Distress Syndrome – Therapeutics, Pathobiology and Prognosis -- Chapter 8 -- Chronic Obstructive Pulmonary Disease - An Update on Therapeutics and Pathophysiological Understanding. . |
| Record Nr. | UNINA-9910416106303321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
COPD : journal of chronic obstructive pulmonary disease
| COPD : journal of chronic obstructive pulmonary disease |
| Pubbl/distr/stampa | New York, NY : , : Marcel Dekker, Inc., , 2004- |
| Descrizione fisica | 1 online resource |
| Disciplina |
616
616.24005 |
| Soggetto topico |
Lungs - Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive Pulmonary Medicine Malalties pulmonars obstructives cròniques Malalties del pulmó |
| Soggetto genere / forma |
Periodicals.
Revistes electròniques. |
| ISSN | 1541-2563 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
Journal of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease |
| Record Nr. | UNINA-9910154550403321 |
| New York, NY : , : Marcel Dekker, Inc., , 2004- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Current pulmonology reports
| Current pulmonology reports |
| Pubbl/distr/stampa | [New York] : , : Springer, , [2015]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Lungs - Diseases
Lung Diseases Infeccions respiratòries Malalties del pulmó Malalties de l'aparell respiratori Pneumologia |
| Soggetto genere / forma |
Periodical
Periodicals. Revistes electròniques. |
| ISSN | 2199-2428 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910481970703321 |
| [New York] : , : Springer, , [2015]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
From thoracic surgery to interventional pulmonology : a clinical guide / / J. Francis Turner, Jr. [and three others], editors
| From thoracic surgery to interventional pulmonology : a clinical guide / / J. Francis Turner, Jr. [and three others], editors |
| Pubbl/distr/stampa | Cham, Switzerland : , : Humana Press, , [2021] |
| Descrizione fisica | 1 online resource (311 pages) |
| Disciplina | 616.2 |
| Collana | Respiratory medicine (New York, N.Y.) |
| Soggetto topico |
Lungs - Diseases - Treatment
Cirurgia toràcica Malalties del pulmó Pneumologia |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-80298-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910502665603321 |
| Cham, Switzerland : , : Humana Press, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Handbook of imaging in pulmonary disease / / Subha Ghosh
| Handbook of imaging in pulmonary disease / / Subha Ghosh |
| Autore | Ghosh Subha |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (231 pages) |
| Disciplina | 616.240754 |
| Soggetto topico |
Lungs - Imaging
Malalties del pulmó Imatges mèdiques Diagnòstic per la imatge |
| Soggetto genere / forma | Llibres electrònics. |
| ISBN | 3-030-68165-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910484210903321 |
Ghosh Subha
|
||
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Image-guided management of COVID-19 lung disease / / Robert L. Bard, editor
| Image-guided management of COVID-19 lung disease / / Robert L. Bard, editor |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , [2021] |
| Descrizione fisica | 1 online resource (163 pages) |
| Disciplina | 616.24 |
| Soggetto topico |
Lungs - Diseases
COVID-19 (Disease) - Alternative treatment Malalties del pulmó COVID-19 Imatges mèdiques |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 3-030-66614-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Foreword -- Acknowledgments -- Contents -- Abbreviations -- 1: Covid-19 Safety Protocols and Protection -- 1.1 Introduction -- 1.2 Survivalism and the Global Demand for Disinfectants -- 1.3 Fighting Back with Bacteria-Killing Solutions -- 1.3.1 Types of Antimicrobial Sanitizers -- 1.4 Commercial Sanitizing for Prevention and Maintenance -- 1.4.1 Five Sanitizing Chemicals Identified Used in Hospitals [18, 19] -- 1.4.2 Sterilants and High-Level Disinfectants [19] -- 1.5 Personal Protective Equipment (PPE) -- 1.6 Sanitizing with UVC Light -- 1.6.1 History of UVC Applications -- 1.7 Epilogue -- 1.8 Summary -- References -- 2: CT Evaluation of COVID-19 Lung Disease -- 2.1 Introduction -- 2.2 Covid-19 Pneumonia -- 2.3 CT Data Image Acquisition -- 2.3.1 Radiologic Findings -- 2.3.2 Early Clinical Course -- 2.3.3 Comparison with Influenza Pneumonia -- 2.4 Image Guided Fusion Treatments -- 2.4.1 Bedside Lung and IVC Imaging -- 2.5 Image Guided Procedures -- 2.5.1 Pneumothorax After Puncture -- 2.6 Radiographic Limitations -- References -- 3: Lung Ultrasound in COVID-19 Disease -- 3.1 Introduction -- 3.2 Basics of Lung Ultrasound Examinations -- 3.2.1 A-lines -- 3.2.2 B-lines -- 3.3 Transducer Selection and Settings -- 3.3.1 Convex Transducers -- 3.3.2 Linear Transducers -- 3.3.3 Phased and Microconvex Transducers -- 3.4 Examination Procedure and Pathologies -- 3.5 Image Fusion -- 3.6 Findings -- 3.7 Conclusions -- References -- 4: Clinical Covid-19 Lung Imaging -- 4.1 Introduction -- 4.2 Findings -- 4.3 Approaches -- 4.4 Clinical Integration -- 4.5 Test Characteristics -- 4.6 Summary -- References -- 5: Pediatric Covid-19 Lung Ultrasound -- 5.1 Introduction -- 5.2 Role of Imaging in Pediatrics -- 5.3 How to Perform Pediatric Lung Ultrasound in the Time of COVID-19.
5.3.1 Ultrasonography Procedure 1 [40] -- 5.3.2 Ultrasonography Procedure 2 [31] -- 5.4 Ultrasonography Technique [29] -- 5.4.1 Other Specific Indications for the Images Acquisition Protocol -- 5.5 Lung Ultrasonography Findings -- 5.6 PIMS-TS and Point-of-Care Ultrasound -- 5.7 Conclusion -- References -- 6: Remote Diagnostics -- 6.1 Introduction -- 6.2 Testing Parameters -- 6.3 Advancing the Remote Scan Movement and Pre-hospital Ultrasound -- 6.4 Initializing the Remote Self-Screening Concept and Process -- 6.5 Remote Ultrasound Benefits for All Patient Types -- 6.5.1 MI: The Mechanical Index -- 6.5.2 TIS: The Soft-Tissue Thermal Index -- 6.6 Remote CT and Sonogram Fusion Diagnostics -- 6.6.1 Data -- 6.7 Salscan Project: Statement of Conclusion -- References -- 7: COVID-19 3D/4D Doppler Imaging -- 7.1 Introduction -- 7.2 Pathophysiology -- 7.3 Vascular Imaging Options -- 7.3.1 Microvessel Imaging -- 7.3.2 Chest Wall Imaging Limitations -- 7.3.3 Vascular Complications -- 7.4 Contrast-Assisted Sonography -- 7.4.1 Pleurisy -- 7.4.1.1 Color-Doppler Sonography of Focal Round Lesions -- 7.5 Large Lung Consolidation -- 7.5.1 Pneumonia -- 7.5.1.1 Color Doppler -- 7.5.1.2 Contrast-Assisted Sonography Pneumonia -- 7.5.1.3 Compressive Atelectasis -- 7.5.1.4 Obstructive Atelectasis -- 7.5.2 Space-Occupying Lesion of the Chest Wall -- 7.5.2.1 Color-Doppler Sonography -- 7.6 Quantifiable Digital Scanning and Image Guided Interventions -- 7.6.1 4D Imaging -- 7.6.2 3D/4D Doppler Histogram -- 7.6.3 Interventions in the Thorax: Indications -- 7.6.4 3D Lung Doppler -- 7.7 Summary -- References -- 8: Multimodality 3D Lung Imaging -- 8.1 Introduction -- 8.2 Stethoscopic Accuracy (Table 8.1) -- 8.3 Lung Sonogram Indications -- 8.3.1 Normal Lung Exam -- 8.3.2 A-Line Artifacts -- 8.3.3 B-Line Artifacts. 8.3.4 C-Line Artifacts -- 8.3.5 Lung Sliding -- 8.3.6 Lung Pulse -- 8.4 Pleural Ultrasound -- 8.4.1 Probe Positions -- 8.5 Consolidation -- 8.5.1 Pneumonia -- 8.5.2 Doppler Flow Patterns -- 8.6 Pneumothorax -- 8.7 Interstitial Syndrome -- 8.7.1 B-Line Pattern Recognition -- 8.8 Atelectasis -- 8.9 Pleural Effusion -- 8.10 Rib Cage -- 8.10.1 Probe Selection -- 8.10.2 Triage Imaging -- 8.11 Pitfalls in Scanning -- 8.12 Limitations of Lung Ultrasound -- 8.13 Limitations of Radiography -- 8.13.1 Best Practices -- 8.13.2 Equipment Specifications -- 8.14 Image Fusion -- 8.14.1 Registration Overview -- 8.14.2 Transformations -- 8.14.3 Interpolators -- 8.14.4 Metrics -- 8.14.5 Optimizers -- 8.15 Acute Care Considerations -- 8.15.1 Bedside IVC Imaging -- 8.16 Image Guided Procedures -- 8.16.1 Pneumothorax After Puncture -- 8.16.2 Pulmonary Fibrosis -- 8.16.3 High Resolution Pleural Imaging -- 8.16.4 Tissue Elastography -- 8.17 Future Directions -- 8.17.1 Algorithm Advances -- 8.17.2 Volumetric Imaging -- 8.17.3 Clinical Testing -- 8.18 Summary -- References -- 9: Respiratory Dynamics: Function and Breath Management -- 9.1 Introduction -- 9.2 Impact of Diseases on Respiratory Function -- 9.3 Probes for Respiratory Function -- 9.3.1 Medical Assessment -- 9.3.2 Clinical Assessment -- 9.4 Exercises to Optimize Breath Management -- 9.5 Summary -- Appendix 1: Aerodynamic Resistance Exercises -- Appendix 2: Physical Stretches: Perform While Standing -- References -- 10: Respiratory Disease with SARS-COV2 Infection -- 10.1 Etiologic Agent, Disease Burden, Transmission, and Clinical Course -- 10.2 Pathogenesis and Clinical Course -- 10.2.1 Viral Entry Through Cell Surface ACE-2 Receptor and Predilection for Respiratory Infection -- 10.2.2 Role of ACE 2 Expression in Other Vital Organs in Overall Severity of Infection. 10.2.3 Inflammatory Immunopathogenesis and Coagulopathies -- 10.2.4 End Organ Damage with Evidence of Complement Activation -- 10.2.5 Clinical Symptoms and Signs -- 10.3 Clinical Assessment -- 10.3.1 Imaging -- 10.3.2 Therapies Under Evaluation for Managing Severe COVID-19 Disease -- 10.4 Clinical Perspective on Available Data -- References. |
| Record Nr. | UNINA-9910492140903321 |
| Cham, Switzerland : , : Springer, , [2021] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
